Oncological Outcomes in Bacillus Calmette-Guérin–naïve High-risk Non–muscle-invasive Bladder Cancer Patients: A Systematic Review on Current Treatment Strategies and Future PerspectivesMattia Longoni, Marco Moschini, Ekaterina Laukhtina et al.|European Urology Oncology|2025Cited by 43
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high–grade non-muscle-invasive urothelial bladder cancerWojciech Krajewski, Ekaterina Laukhtina, Júlia Aumatell et al.|Urologic Oncology Seminars and Original Investigations|2022Cited by 29
The Role of Mitomycin C in Intermediate-risk Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysisPietro Scilipoti, Marco Moschini, Aleksander Ślusarczyk et al.|European Urology Oncology|2024Cited by 29
Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non–muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk DynamicsJosé Daniel Subiela, F.J. Burgos Revilla, Wojciech Krajewski et al.|European Urology Oncology|2024Cited by 20
Outcomes of <scp>BCG</scp> vs upfront radical cystectomy for high‐risk non‐muscle‐invasive bladder cancerPietro Scilipoti, Marco Moschini, Mattia Longoni et al.|British Journal of Urology|2025Cited by 12